David Olagnier

16PUBLICATIONS
99CO-AUTHORS
Reaction engineering (excl. nuclear reactions)Medical biochemistry - proteins and peptides (incl. medical proteomics)Biologically active moleculesImmunogenetics (incl. genetic immunology)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Feb 20, 2026
NRF2 activators and the inhibitor of nuclear export, selinexor, restrict coronaviruses by targeting a network involving ACE2, TMPRSS2, and XPO1 through an NRF2-independent mechanism.

Fakhar H Waqas, Leandro Silva da Costa, Francisco J Zapatero-Belinchón

|Oct 28, 2025
Proteolytic profiling of human plasma reveals an immunoactive complement C3 fragment.

Fatih Demir, Elina Kovalenko, Moritz Lassé

|Aug 21, 2025
Fragment-Based Drug Discovery of Novel High-affinity, Selective, and Anti-inflammatory Inhibitors of the Keap1-Nrf2 Protein-Protein Interaction.

Chunyu Lin, Dilip Narayanan, Marilia Barreca

|Mar 26, 2025
Dual faces of itaconate and its derivatives: exploring diverse biological functions in immunity and infectious diseases.

Cecilie Poulsen, Dominic G Roy, David Olagnier

|Dec 21, 2024
HSP60 controls mitochondrial ATP generation for optimal virus-specific IL-21-producing CD4 and cytotoxic CD8 memory T cell responses.

Nazanin Ghahari, Saina Shegefti, Mahsa Alaei

|Dec 20, 2024
Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

Naziia Kurmasheva, Aida Said, Boaz Wong

Pageof 3

Frequent Collaborators

4 joint publications

Esben B Svenningsen

4 joint publications

Søren R Paludan

4 joint publications

Christian K Holm

4 joint publications

Markus M Rinschen